Merus (MRUS) Stock Price, News & Analysis

Company Overview

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development. Key programs are being evaluated in solid tumors and hematological malignancies, with a focus on innovative mechanisms of action that harness T cell redirection, immune checkpoint modulation and co-stimulatory pathways. In addition to its internal development efforts, Merus collaborates with strategic partners to advance select programs and expand its therapeutic reach.

Headquartered in Utrecht, the Netherlands, Merus maintains operations in both Europe and the United States, supporting global clinical trials and regulatory activities. The company completed its initial public offering on the Nasdaq stock market in October 2018, and its research sites extend from the Dutch biotech hub to a dedicated U.S. presence in Boston’s ecosystem.

Merus is led by a management team with extensive experience in oncology drug development and commercialization. Under the leadership of Chief Executive Officer Ton Logtenberg, the company continues to advance its bispecific antibody platform, aiming to deliver transformative treatments for patients with unmet medical needs.

Key Stats

• Today's Range: $87.14 to $96.86
• 50-Day Range: $90.00 to $97.01
• 52-Week Range: $37.92 to $97.14
• Volume: 2.73 million shs
• Average Volume: 1.51 million shs
• Market Capitalization: $6.83 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $96.92
• Consensus Rating: Reduce

Company Calendar

• Last Earnings: 8/05/2025
• Today: 8/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MRUS
• CIK: 1651311
• Web: www.merus.nl
• Phone: (130) 253-8800
• Fax: N/A
• Employees: 37
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Merus: $96.92
• High Price Target: $97.00
• Low Price Target: $96.00
• Potential Upside/Downside: +7.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.93
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$215.33 million
• Net Margins: -673.31%
• Pretax Margin: -653.35%
• Return on Equity: -52.99%
• Return on Assets: -44.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.97
• Quick Ratio: 7.97

Sales & Book Value

• Annual Sales: $36.13 million
• Price / Sales: 188.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.46 per share
• Price / Book: 9.51

Miscellaneous

• Outstanding Shares: 75,850,000
• Free Float: 73,041,000
• Market Cap: $6.83 billion
• Optionable: Optionable
• Beta: 1.06